*By Carlo Versano*
Tilray, the Canadian cannabis company swiftly becoming one of the most talked-about stocks of the year, was up as much as 50 percent on Wednesday morning, leading a continued bull run in pot stocks and putting its market cap above established companies like Macy's and Viacom.
Tilray President and CEO Brendan Kennedy [said](https://www.cnbc.com/2018/09/18/tilray-ceo-investing-in-pot-great-hedge-for-alcohol-drug-companies.html) on Tuesday that pharmaceutical and alcohol companies need to consider partnering with cannabis suppliers as a hedge against their core businesses. Those comments, along with the halo effect of Tilray saying it earned approval to provide medical marijuana for a U.S. clinical study, helped send shares over $200 apiece ー they debuted on the Nasdaq at $17 just two months ago.
Citron Research, whose bearish bets on stocks can be market-moving, [tweeted](https://twitter.com/CitronResearch/status/1042395769372909568) on Wednesday morning that Tilray's run is "beyond comprehension" and that it will continue to be short the stock "until rationality sets in." That followed another less-than-favoratble [piece](https://www.barrons.com/articles/marijuana-stocks-coca-cola-aurora-1537235413) from Barron's that said, "even the bulls see a bubble."
But with the legal sales of cannabis in Canada now less than a month away ー and investors jockeying for position ー the sector could continue on its high, at least in the short-term. Shares of both Canopy Growth and Aurora Cannabis have also seen double-digit percent increases since they've received interest from Constellation and Coca-Cola, respectively.
Walmart, which became the nation’s largest retailer by making low prices a priority, has found itself in a place it’s rarely been: Warning customers that prices will rise for goods ranging from bananas to car seats.
Chris Beauchamp, Chief Market Analyst at IG International, joins J.D. Durkin to give analysis on the recent trade truce between the U.S. and China. Watch!
Shan Aggarwal, VP of Corporate and Business Development at Coinbase, discusses the company's acquisitio of Deribit as it heads into the S&P 500. Watch!
American businesses that rely on Chinese goods are reacting with muted relief after the U.S. and China agreed to pause their exorbitant tariffs on each other’s products for 90 days. Many companies delayed or canceled orders after President Donald Trump last month put a 145% tariff on items made in China. Importers still face relatively high tariffs, however, as well as uncertainty over what will happen in the coming weeks and months. The temporary truce was announced as retailers and their suppliers are looking to finalize their plans and orders for the holiday shopping season. They’re concerned a mad scramble to get goods onto ships will lead to bottlenecks and increased shipping costs.
Shopping expert Trae Bodge discusses how talks between the U.S. and China is good news for now, but uncertainty remains for back-to-school and the holidays.
Jake Traylor, White House reporter at Politico, joins Cheddar to discuss how Trump is aiming to lower drug prices and how it differs from Biden's approach.
